Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Long-term non-progressors (LTNP) control Human Immunodeficiency Virus (HIV) replication.
• LTNP subjects provide valuable insights for developing antibody and active vaccination strategies.
• Understanding HIV epitopes in LTNP can identify biomarkers for AIDS progression resistance.

Purpose of the Study:

• To identify common epitopes on the HIV gp160 protein recognized by LTNP sera.
• To analyze the conservation of identified epitopes across different HIV clades.
• To evaluate the viral inhibition capabilities of antibodies generated against a specific epitope.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to screen five LTNP sera samples for epitope binding.
• Peptides with high serum binding were selected and assessed for cross-clade conservation.
• Antibodies were generated against a selected epitope using a chimeric peptide in BALB/c mice.
• Viral inhibition assays were performed using both mouse-generated antibodies and LTNP sera.

Main Results:

• Four LTNP sera samples (2, 3, 4, and 5) exhibited high antibody titers and significant inhibition of syncytia formation in vitro.
• A monoclonal antibody, CL3, was generated against a key epitope, allowing comparison of neutralizing capabilities.
• Cytokine analysis revealed decreased levels of I-309 and IGFBP-1, with increased levels of TIMP-1 and NAP-2 in LTNPs.

Conclusions:

• LTNP samples are valuable for discovering novel anti-viral epitopes.
• Identified epitopes and associated antibody responses may serve as predictors of resistance to HIV progression to AIDS.